Alpha-defensins: risk factor for thrombosis in COVID-19 infection

알파 방어소: COVID-19 감염의 혈전증 위험 인자

Published on
Journal: British Journal of Haematology
[저자] Suhair Abdeen, Khalil Bdeir, Rami Abu-Fanne, Emad Maraga, Mohamed Higazi, Nigar Khurram, Michael Feldman, Charuhas Deshpande, Leslie A Litzky, Samuel N Heyman, Kathleen T Montone, Douglas B Cines, Abd Al-Roof Higazi
[Category] SARS, 비임상, 임상,
PMC URL    [DOI] 10.1111/bjh.17503    
[Article Type] Clinical Trial
[Source] PMC

Abstract
The inflammatory response to SARS/CoV-2 (COVID-19) infection may contribute to the risk of thromboembolic complications. α-Defensins, antimicrobial peptides released from activated neutrophils, are anti-fibrinolytic and prothrombotic in vitro and in mouse models. In this prospective study of 176 patients with COVID-19 infection, we found that plasma levels of α-defensins were elevated, tracked with disease progression/mortality or resolution and with plasma levels of interleukin-6 (IL-6) and D-dimers. Immunohistochemistry revealed intense deposition of α-defensins in lung vasculature and thrombi. IL-6 stimulated the release of α-defensins from neutrophils, thereby accelerating coagulation and inhibiting fibrinolysis in human blood, imitating the coagulation pattern in COVID-19 patients. The procoagulant effect of IL-6 was inhibited by colchicine, which blocks neutrophil degranulation. These studies describe a link between inflammation and the risk of thromboembolism, and they identify a potential new approach to mitigate this risk in patients with COVID-19 and potentially in other inflammatory prothrombotic conditions.
Keywords: COVID-19 infection; inflammation; interleukin-6; thrombosis; α-defensins.

All Keywords
【저자키워드】 Inflammation, thrombosis, interleukin-6, COVID-19 infection, breath, α-defensins., 【초록키워드】 COVID-19, Neutrophils, immunohistochemistry, thrombosis, IL-6, Prospective Study, neutrophil, Infection, interleukin-6, lung, risk, in vitro, fibrinolysis, Coagulation, interleukin, COVID-19 infection, Thromboembolism, peptides, antimicrobial peptides, plasma, Colchicine, vasculature, D-dimers, Mouse models, disease, COVID-19 patients, Blood, Activated neutrophils, Inflammatory response, Inflammatory, Plasma levels, thromboembolic, neutrophil degranulation, thromboembolic complications, antimicrobial peptide, thrombi, block, mitigate, approach, prothrombotic, procoagulant, stimulated, identify, inhibited, elevated, contribute, released, conditions, inhibiting, patients with COVID-19, 【제목키워드】 thrombosis, risk factor,
{{{ 추상적인 }}} SARS/CoV-2(COVID-19) 감염에 대한 염증 반응은 혈전색전증 합병증의 위험에 기여할 수 있습니다. 활성화된 호중구에서 방출되는 항균성 펩타이드인 α-Defensins는 시험관 내 및 마우스 모델에서 항섬유소 용해 및 전혈전성입니다. COVID-19 감염 환자 176명을 대상으로 한 이 전향적 연구에서 우리는 α-defensins의 혈장 수준이 상승했으며 질병 진행/사망률 또는 해소와 함께 추적되었으며 인터루킨-6(IL-6) 및 D-이량체의 혈장 수준이 추적됨을 발견했습니다. . Immunohistochemistry는 폐 혈관 구조와 혈전에서 α-defensins의 강렬한 침착을 보여주었습니다. IL-6은 호중구에서 α-방어신의 방출을 자극하여 응고를 가속화하고 인간 혈액의 섬유소 용해를 억제하여 COVID-19 환자의 응고 패턴을 모방합니다. IL-6의 응고 촉진 효과는 호중구 탈과립을 차단하는 콜히친에 의해 억제되었습니다. 이 연구는 염증과 혈전색전증의 위험 사이의 연관성을 설명하고 COVID-19 환자 및 잠재적으로 다른 염증성 혈전성 질환에서 이러한 위험을 완화할 수 있는 잠재적인 새로운 접근 방식을 확인합니다. {{ 키워드: }} 코로나19 감염; 염증; 인터루킨-6; 혈전증; α-방어신.